Clinical trials
Phase 2 Neurofibroma, Plexiform trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2004 | 1 |
| 2006 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Terminated | 4 |
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Withdrawn | 3 |
| Unknown status | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| University of Alabama at Birmingham | 3 |
| Indiana University | 2 |
| St. Justine's Hospital | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| AstraZeneca | 1 |
| Children's Hospital of Philadelphia | 1 |
| Healx Limited | 1 |
| Mayo Clinic | 1 |
| Novartis Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neurofibroma, Plexiform | 23 |
| Neurofibromatosis 1 | 17 |
| Neurofibromatoses | 7 |
| Neurofibroma | 3 |
| Brain Neoplasms | 1 |
| Glioma | 1 |
| Heredodegenerative Disorders, Nervous System | 1 |
| Neoplasms, Nerve Tissue | 1 |
| Nerve Sheath Neoplasms | 1 |
| Peripheral Nervous System Diseases | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.